Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: A systematic review and meta-analysis

摘要: Introduction Previous studies of the association brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with antidepressant efficacy are inconsistent. Thus, we conducted a systematic review and meta-analysis. Methods We searched MEDLINE, PubMed, EMBASE, Chinese Databases (Biomedical Literature Database, National Knowledge Infrastructure, Weipu, WanFang) up to March 2013 for relevant (584 retrieved, 16 met inclusion criteria). We six comparisons both response remission rates three genotypes in Caucasians Asians (4 weeks or ≥6 weeks; selective serotonin reuptake inhibitors [SSRIs], serotonin-noradrenaline inhibitors, or mixed antidepressants). Results Met carriers had better rate than Val/Val. In Asians, Met carrier was positively associated (odds ratio; 95% confidence interval: 1.48; 1.02–2.14) SSRI group (1.81; 1.10–2.97) treatments ≥6 weeks. Met/Val showed positive versus homozygotes (1.60; 1.20–2.13) (mixed antidepressant, 1.36; 1.04–1.77; SSRI, 1.55; 1.11–2.17). There weak effect Val/Val SSRIs time, 2.07; 1.48–2.89; ≥6 weeks, 2.25; 1.53–3.32). For remission, (1.71; 1.09–2.68, only). Discussion Our meta-analysis confirms effects BDNF on Asians. This may be dependent ethnic origin because lesser influence race studies. Antidepressants were more effective groups treatment duration future investigators should carefully consider their outcome observation end point.